Trends in mean age at diagnosis by exposure category, 1995–2019 (n = 2,621). by Katia Giguère (146393)

Subjects:

The standardized mean difference in PC-ASPECTS scores between patients with unfavorable and favorable outcomes. by Wei-Zhen Lu (10150728)

Mean arterial pressure (MAP). by Annelie Barrueta Tenhunen (9268152)

Longevity (mean±SEM) of adult males, females, and host-provided females (females + hosts) of the pupal parasitoid, <i>Pachycrepoideus vindemmiae</i> (Hymenoptera: Pteromalidae), of... by Cherre S. Bezerra Da Silva (7026926)

Combined illusion score index across conditions (NI: Non-Illusion; NIT: Non-Illusion Tactile; MS: Multisensory; UV: Unimodal Visual). by Kirralise J. Hansford (20670869)

Cumulative distribution of EQ-5D-3L utilities decreasingly ordered before and after the onset of cutaneous leishmaniasis symptoms. by Janaína de Pina Carvalho (12152812)

Cardamonin induced apoptosis and decreased the MMP of ovarian cancer cells. by Peiguang Niu (17044532)

Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log₁₀ within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”

mTORC1 hyperactivation led to a decreased autophagic activity in the podocytes. by Wakiko Iwata (8600457)

Hypothesis that explains and predicts expansion of ages of KD due to decreased IgG levels. by Hiromi Yamaguchi (2396248)

Fig. S10: Vegetational change during the Middle–Late Pennsylvanian transition in western Pangaea by Sandra Schachat (3281730)

Estimated attributable cases related to total and port-sourced NO₂, PM₁₀ and PM_2.5. by Natalie Mueller (3406370)

Mean percentage changes (95% CI) in total testosterone, SHBG and free testosterone (mITT analysis). by Chanel Avenant (409756)

Intrathecal injection of IGF2 siRNA decreases IGF2 protein expression in the spinal cord. by Wei-Hung Chan (11785304)

Stable overexpression of PFKFB3-5 in HEK-293 and U87 cells leads to decreased cell viability and proliferation while leaving transcriptional profile of PFKFB3-1 and -11 unaltered. by Ulli Heydasch (11091062)

The mean decreasing Gini importance OTU importance estimated with random forests and bacterial 16S DNA sequences from striped skunk fecal samples. by Matthew W. Hopken (3251058)

Plasma DEX concentrations in C57BL/6 VD₃ sufficient and deficient mice on a discontinuous DEX regimen. by Kavya Annu (11587215)

Induction of duodenal and hepatic Cyps in VD₃ deficient mice after DEX treatment. by Kavya Annu (11587215)